What Do Patients Want Doctors to Know About Breast Cancer Recurrence?What Do Patients Want Doctors to Know About Breast Cancer Recurrence?
(MedPage Today) — This article includes a first-person perspective from early breast cancer patient Lina. Lina was compensated for her time by Novartis.
Some patients with hormone receptor (HR)-positive, human epidermal growth factor receptor…
Slow-dividing breast cancer cells may explain relapses decades after treatmentSlow-dividing breast cancer cells may explain relapses decades after treatment
A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment. Published in Nature Communications, the research reveals rogue cells that change their programming to allow them to divide at a remarkably slow pace, meaning they could form microscopic tumors that silently tick away in distant organs, evading detection for decades.
Ozempic delivers major weight loss in adults over 65, study findsOzempic delivers major weight loss in adults over 65, study finds
A major new analysis suggests semaglutide (Ozempic, Wegovy) works remarkably well in adults over 65, helping many lose substantial amounts of weight while improving heart and metabolic health. Participants taking the drug lost over 15% of their body weight on average — far more than those receiving placebo treatment. Many also moved out of obesity Read More
GLP-1 Receptor Agonists and CancerGLP-1 Receptor Agonists and Cancer
Oncology Oncology
Survival and Recurrence With GLP-1 Receptor Agonists in Breast CancerSurvival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
This cohort study of more than 800 000 patients with breast cancer evaluates the association between glucagon-like peptide-1 receptor agonist use and 10-year mortality and recurrence-free survival. This cohort study of more than 800 000 patients with breast cancer evaluates the association between glucagon-like peptide-1 receptor agonist use and 10-year mortality and recurrence-free survival.
Pooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 yearsPooled analysis reveals semaglutide shows good efficacy in older adults aged over 65 years
A new analysis of the STEP trials carried out by semaglutide manufacturer Novo Nordisk has analyzed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations. The study is by Prof Luca Busetto from Read More
Could the ‘Ozempic Era’ shift blame for obesity from individuals to the food industry?Could the ‘Ozempic Era’ shift blame for obesity from individuals to the food industry?
An essay presented at the European Congress on Obesity in Istanbul, Turkey (12–15 May) suggests that a new age of obesity drugs could shift the blame for living with obesity from individuals to the food industry—just as smoking has been blamed on the tobacco industry and, to a lesser extent, alcohol consumption on the alcohol Read More
Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatmentStudy shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment
New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to a relatively lower risk of obesity-related conditions. The study is Read More
Study shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatmentStudy shows benefits in obesity-linked conditions of losing more weight with GLP-1 treatment
New research presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that, following treatment for obesity or diabetes or both, using incretin-based drugs, losing more weight versus less weight, and losing a little weight versus gaining weight, both lead to a relatively lower risk of obesity-related conditions. The study is Read More
Technology receives FDA approval for breast cancer treatmentTechnology receives FDA approval for breast cancer treatment
More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause them.